Avoro Capital Advisors’s Mersana Therapeutics MRSN Stock Holding History

Avoro Capital Advisors’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-255,000	Closed	-$21M	–	48
2023 Q2	$21M	Sell	255,000 -47,000	-16%	-$6.88M	0.28%	32
2023 Q1	$31M	Hold	302,000	–	–	0.46%	27
2022 Q4	$44.2M	Hold	302,000	–	–	0.66%	25
2022 Q3	$51M	Hold	302,000	–	–	0.94%	19
2022 Q2	$34.9M	Buy	302,000 +30,000	+11%	+$2.82M	0.69%	23
2022 Q1	$27.1M	Hold	272,000	–	–	0.5%	30
2021 Q4	$42.3M	Hold	272,000	–	–	0.72%	22
2021 Q3	$64.1M	Hold	272,000	–	–	1.01%	20
2021 Q2	$92.3M	Hold	272,000	–	–	1.61%	16
2021 Q1	$110M	Hold	272,000	–	–	1.9%	15
2020 Q4	$181M	Hold	272,000	–	–	3.12%	11
2020 Q3	$127M	Buy	272,000 +12,000	+5%	+$6.06M	1.8%	13
2020 Q2	$152M	Buy	+260,000	New	+$88.8M	3.01%	12

Other funds holding MRSN

EcoR1 Capital San Francisco, California $2.34B AUM 204.53% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Balyasny Asset Management

Balyasny Asset Management Chicago, Illinois $50.9B AUM 42.89% 1-Year Est. Return

Silverarc Capital Management Boston, Massachusetts $849M AUM 470.8% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Affinity Asset Advisors New York $1.71B AUM 374.45% 1-Year Est. Return